This article reviews the role of venetoclax (Venclexta®) as a backbone therapy in the updated ESMO guideline on targeted agents for the treatment of chronic lymphocytic leukaemia, in the context of recent changes to funded access to venetoclax.
Please login below to download this issue (PDF)